Optimizing migraine therapy: evidence-based and patient-centered care

References

• Headache Classification Subcommittee of the International Headache Society. The International Classification of Headache Disorders. 2nd Edition. Cephalalgia24(Suppl. 1), 1–151 (2004).
   Web of Science ®Google Scholar
• Lipton RB, Bigal ME. The epidemiology of migraine. Am. J. Med.118(Suppl. 1), S3–S10 (2005).
   PubMedGoogle Scholar
• Leonardi M, Steiner TJ, Scher AT, Lipton RB. The global burden of migraine: measuring disability in headache disorders with WHO’s Classification of Functioning, Disability, and Health. J. Headache Pain6, 429–440 (2005).
   PubMedGoogle Scholar
• Cady R, Schrieber C, Farmer K, Sheftell F. Primary headaches: a convergence hypothesis. Headache42, 204–216 (2002).
   PubMed Web of Science ®Google Scholar
• Lipton RB, Scher AI, Kolodner K et al. Migraine in the United States: epidemiology and patterns of health care use. Neurology58, 885–894 (2002).
   PubMed Web of Science ®Google Scholar
• Lipton RB, Diamond SD, Reed M, Diamond ML, Stewart WF. Migraine diagnosis and treatment: results from the American Migraine Study II. Headache41, 638–645 (2001).
   PubMed Web of Science ®Google Scholar
• Stewart WF, Lipton RB, Celentano DD, Reed ML. Prevalence of migraine headache in the United States: relation to age, income, race, and other sociodemographic factors. JAMA267, 64–69 (1992).
   PubMed Web of Science ®Google Scholar
• Osterhaus JT, Guterman DI, Planchetka JR. Healthcare resources and lost labor costs of migraine headache in the U.S. Pharmcol. Econ.2, 67–76 (1992).
   PubMedGoogle Scholar
• Hu XH, Markson LE, Lipton RB, Stewart WF, Berger ML. Burden of migraine in the United States: disability and economic costs. Arch. Intern. Med.159, 813–838 (1999).
   PubMed Web of Science ®Google Scholar
• Kaniecki RG. The impact of migraine: how this disorder affects us all. Consultant40, S25–S28 (2000).
   Google Scholar
• WHO. Headache disorders and public health. Geneva, Switzerland: Department of Mental Health and Substance Dependence, Noncommunicable Diseases and Mental Health Cluster, WHO (2000).
   Google Scholar
• Lipton RB, Bigal ME, Amatniek JC, Stewart WF. Tools for diagnosing migraine and measuring its severity. Headache44, 387–398 (2004).
   Google Scholar
• Holroyd KA, Cordingley GE, Pingel JD et al. Enhancing the effectiveness of abortive therapy: a controlled evaluation of self-management training. Headache29, 148–153 (1989).
   PubMed Web of Science ®Google Scholar
• Blumenfeld A, Tischio M. Center of excellence for headache care: group model at Kaiser Permanente. Headache43, 431–440.
   Google Scholar
• Marcus DA. Establishing a standard of speed for assessing the efficacy of serotonin agonists. Arch. Neurol.58, 1056–1058 (2001).
   PubMed Web of Science ®Google Scholar
• Santanello NC, Davies G, Allen C, Kramer M, Lipton R. Determinants of migraine-specific quality of life. Cephalalagia22, 680–685 (2002).
   PubMed Web of Science ®Google Scholar
• Diener HC, Brune K, Gerber WD, Gobel H, Pfaffenrath V. Treatment of migraine attacks and migraine prophylaxis: recommendations of the German Migraine and Headache Society. Med. Monatsschr. Pharm.21, 30–39 (1998).
   Google Scholar
• No author listed. Guidelines for the management of headache. Danish Neurological Society and the Danish Headache Society. Cephalalgia18, 9–22 (1998).
   Google Scholar
• Ducharme J. Canandian Association of Emergency Physician Guidelines for the acute management of migraine headache. J. Emerg. Med.17, 137–144 (1999).
   PubMed Web of Science ®Google Scholar
• Geraud G, Lanteri-Minet M, Lucas C, Valade D. French guidelines for the diagnosis and management of migraine in adults and children. Clin. Ther.26, 1305–1318 (2004).
   PubMed Web of Science ®Google Scholar
• No author listed. Guidelines for the treatment of migraine crisis. Concensus of the Sociedade Brasileira de Cefaleia. Ad Hoc Committee. Arq. Neuropsiquiatr.58, 371–389 (2000).
   Google Scholar
• Silberstein SD, for the US Headache Consortium. Practice parameter: evidence-based guidelines for migraine headache. Neurology55, 754–762 (2003).
   Google Scholar
• Devine JW, Farley JF, Hadsall RS. Patterns and predictors of prescription medication use in the management of headache: findings from the 2000 Medical Expenditure Panel Survey. Headache45, 1171–1180 (2000).
   Google Scholar
• Gladstone JP, Gawel M. Newer formulations of the triptans: advances in migraine management. Drugs63, 2285–2305 (2003).
   PubMed Web of Science ®Google Scholar
• Ferrari MD, Roon KI, Lipton RB, Goadsby PJ. Triptans in acute migraine treatment: a meta-analysis of 53 trials. Lancet358, 1668–1675 (2001).
   PubMed Web of Science ®Google Scholar
• Dodick D, Lipton RB, Martin V et al. Triptan Cardiovascular Safety Expert Panel. Consensus statement: cardiovascular safety profile of triptans (5-HT agonists) in the acute treatment of migraine. Headache44, 414–425 (2004).
   PubMed Web of Science ®Google Scholar
• Glaxo SmithKline. Imitrex (sumatriptan) prescribing information. Research Triangle Park, NC (2001).
   Google Scholar
• GlaxoSmithKline. Amerge (naratriptan) prescribing information. Research Triangle Park, NC (2001).
   Google Scholar
• AstraZeneca Pharmaceuticals LP. Zomig (zolmitriptan) prescribing information. Wilmington DE (2001).
   Google Scholar
• Merck and Co. Maxalt (rizatriptan) prescribing information. West Point, PA (2001).
   Google Scholar
• Endo Pharmaceuticals. Frova (frovatriptan) prescribing information. Chadds Ford, PA (2004).
   Google Scholar
• Ortho-McNeil Neurologics, Inc. Axert (almotriptan) prescribing information. Titusville, NJ (2004).
   Google Scholar
• Pfizer Inc. Relpax (eletriptan) prescribing information. New York, NY (2005).
   Google Scholar
• Dodick DW, Silberstein S, Dahlof CG. Is there a preferred triptan? Headache42(1), 1–7 (2002).
   Google Scholar
• Pringsheim T, Gawel M. Triptans: are they all the same? Curr. Pain Headache Rep.6(2), 140–146 (2002).
   Google Scholar
• Saper J. What matters is not the difference between the triptans, but the differences between patients. Arch. Neurol.58, 1481–1482 (2001).
   PubMed Web of Science ®Google Scholar
• Geraud G, Olesen J, Pfaffenrath V et al. Comparison of the efficacy of zolmitriptan and sumatriptan: issues in migraine trial design. Cephalalgia20(1), 30–38 (2000).
   PubMed Web of Science ®Google Scholar
• Mathew NT, Loder EW. Evaluating the triptans. Am. J. Med.118(Suppl. 1), S28–S35 (2005).
   PubMed Web of Science ®Google Scholar
• Lipton RB, Stewart WF. What do migraineurs want? Headache39(Suppl. 2), S20–S26 (1999).
   Google Scholar
• Wenzel RG, Sarvis CA, Krause ML. Over-the-counter drugs for acute migraine attacks: literature review and recommendations. Pharmacotherapy23, 494–505 (2003).
   PubMed Web of Science ®Google Scholar
• Gray RN, McCrory DC, Eberlein K et al. Self-administered Drug treatments for acute migraine headache. Technical review 2.4. Prepared by the Agency for Health Care Policy and Research under Contract No. 290–94–2025. Available from the National Technical Information Service. NTIS Accession No. 127854. Duke University Center for Clinical Health Policy Research; Durham, NC (1999).
   Google Scholar
• Pfaffenrath V, Scherzer S. Analgesics and nsaids in the treatment of acute migraine attack. Cephalagia15(Suppl. 15), 14–20 (1995).
   PubMed Web of Science ®Google Scholar
• Loder E. Fixed drug combinations for the acute treatment of migraine: place in therapy. CNS Drugs19(9), 769–784 (1995).
   Google Scholar
• Wenzel RG, Sarvis CA. Do butalbital-containing products have a role in the management of migraine? Pharmacotherapy22, 1029–1035 (2002).
   PubMed Web of Science ®Google Scholar
• Young WB, Siow HC. Should butalbital-containing analgesics be banned? Yes. Curr. Pain Headache Rep.6, 151–155 (2002).
   Google Scholar
• Richard B. Lipton RB, Bigal ME. Opioid therapy and headache: a cause and a cure. Neurology62, 1662–1663 (2004).
   Google Scholar
• Saper JR, Lake AE 3rd, Hamel RL et al. Daily scheduled opioids for intractable head pain: long-term observations of a treatment program. Neurology62, 1687–1694 (2004).
   PubMedGoogle Scholar
• Diamond S, Diamond ML, Silberstein S. Winner P. Advances in migraine management: the roles of acute, prophylactic, and rescue medications. Headache Quarterly12, 183–194 (2001).
   Google Scholar
• Lipton RB, Stewart WF, Stone Am, Lainez JHA, Sawyer JPC. Stratified care versus step care for migraine. JAMA284, 2599–2605 (2000).
   PubMed Web of Science ®Google Scholar
• Wenzel R. Triptan quantity limits. J. Managed Care Pharmacy8(3), 182–184 (2005).
   Google Scholar
• Sculpher M, Millson D, Meddis D, Poole L. Cost-effectiveness analysis of stratified versus stepped care strategies for acute treatment of migraine: the Disability in Strategies for Care (DISC) Study. Pharmacoeconomics20, 91–100 (2002).
   PubMed Web of Science ®Google Scholar
• Williams P, Dowson AJ, Rapoport AM, Sawyer J. The cost-effectiveness of stratified care in the management of migraine. Pharmacoeconomics19, 819–829 (2001).
   PubMed Web of Science ®Google Scholar
• Bigal ME, Rapoport AM, Bordini CA, Tepper SJ, Sheftell FD, Speciali JG. Burden of migraine in Brazil: estimate of cost of migraine to the public health system and an analytical study of the cost–effectiveness of a stratified model of care. Headache43, 742–754 (2001).
   Google Scholar
• Scher AI, Stewart WF, Ricci JA, Lipton RB. Factors associated with the onset and remission of chronic daily headache in a population-based study. Pain106(1–2), 81–89 (2003).
   PubMed Web of Science ®Google Scholar
• Wenzel RG, Schwartz C, Pariyara RA. Topiramate for migraine prevention: a literature review. Pharmacotherapy26, 375–387 (2006).
   Google Scholar
• Holroyd KA, France JL, Cordingley GE et al. Enhancing the effectiveness of relaxation-thermal biofeedback training with propranolol hydrochloride. J. Consult Clin. Psychol.63, 327–330 (1995).
   PubMed Web of Science ®Google Scholar